(3AS,6AS)-六氢吡咯并[3,4-B]吡咯-1(2H)-羧酸叔丁酯 | 370880-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (3AS,6AS)-六氢吡咯并[3,4-B]吡咯-1(2H)-羧酸叔丁酯
• 英文名称: tert-butyl (3aS,6aS)-octahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate
• 英文别名: (3aR,6aR)-hexahydro-pyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester；tert-butyl (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrole-1 (2H)-carboxylate；Tert-butyl (3AS,6AS)-hexahydropyrrolo[3,4-B]pyrrole-1(2H)-carboxylate；tert-butyl (3aS,6aS)-3,3a,4,5,6,6a-hexahydro-2H-pyrrolo[2,3-c]pyrrole-1-carboxylate
• CAS: 370880-16-3
• 化学式: C₁₁H₂₀N₂O₂
• 分子量: 212.292
• InChiKey: OIKZNKIPPFFTKA-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3AS,6AS)-六氢吡咯并[3,4-B]吡咯-1(2H)-羧酸叔丁酯 、 6-chloro-pyrazine-2-carboxylic acid 3-methylphenyl amide 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 21.0h， 生成 (3aS,6aS)-tert-butyl 5-(6-(m-tolylcarbamoyl)pyrazin-2-yl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate
  参考文献：
  名称：

  Structure–Activity Studies of Diazabicyclo[3.3.0]octane-Substituted Pyrazines and Pyridines as Potent α4β2 Nicotinic Acetylcholine Receptor Ligands

  摘要：

  A series of diazabicyclo[3.3.0]octane substituted pyridines and pyrazines was synthesized and characterized at the alpha 4 beta 2 neuronal nicotinic acetylcholine receptor (nAChR). The compounds were designed to mimic the profile of ABT-089, high affinity binding ligand for the alpha 4 beta 2 nAChR, with limited agonist activity. Carboxamide derivatives of 3-(diazabicyclo[3.3.0]octane)-substituted pyridines or 2-(diazabicyclo[3.3.0]octane)-substituted pyrazines were found to have the desired binding and activity profile. The structure-activity relationship of these compounds is presented.

  DOI：

  10.1021/jm201045m
• 作为产物：
  描述：

  tert-butyl 5-benzylhexahydropyrrolo[3,4-b]pyrrole-1(2H)carboxylate 在 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 四氢呋喃 为溶剂， 70.0 ℃ 、3.0 MPa 条件下， 反应 16.0h， 以95%的产率得到(3AS,6AS)-六氢吡咯并[3,4-B]吡咯-1(2H)-羧酸叔丁酯
  参考文献：
  名称：

  ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR

  摘要：

  本发明公开了一类异喹啉磺酰衍生物作为RHO激酶抑制剂，以及其药物组合物，并涉及它们的药用可接受用途。具体而言，本发明涉及如式(I)所示的化合物，或其药用可接受的盐。

  公开号：

  US20170037050A1

文献信息

• Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones
  申请人：Armour R. Duncan

  公开号：US20080085884A1

  公开（公告）日：2008-04-10

  The present invention provides for MCHR1 antagonist compounds of formula (I) and the pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein the substituents are as defined herein, and the pharmaceutically acceptable salts, solvates and prodrugs thereof, which are useful in treating diseases or conditions wherein antagonism of the MCHR1 receptor is beneficial.

  本发明提供了式（I）的MCHR1拮抗剂化合物及其药用盐、溶剂合物和前药，其中取代基如本文所定义，并且其药用盐、溶剂合物和前药，可用于治疗对MCHR1受体拮抗有益的疾病或症状。
• INDOLE CARBOXAMIDE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160115126A1

  公开（公告）日：2016-04-28

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR 4 or N; R 1 , R 2 , R 3 , R 4 , and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物： 或其盐，其中：X为CR 4 或N；R 1 ，R 2 ，R 3 ，R 4 和A在此处定义。还揭示了使用这些化合物作为Bruton's酪氨酸激酶（Btk）抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域的疾病或疾病的进展方面非常有用，如自身免疫疾病和血管疾病。
• COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20160235734A1

  公开（公告）日：2016-08-18

  Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

  具有本公式I定义的化合物既作为毒蕈碱受体拮抗剂又作为β2肾上腺素能受体激动剂，并且用于治疗支气管阻塞和炎症性疾病。
• [EN] PYRAZOLOTRIAZINES<br/>[FR] PYRAZOLOTRIAZINES
  申请人：BAYER AG

  公开号：WO2021116178A1

  公开（公告）日：2021-06-17

  The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

  本发明提供了具有通用公式（I）的化合物，其中X，R1，R2和R3如本文所述和定义，制备所述化合物的方法，用于制备所述化合物的有用中间化合物，包含所述化合物的药物组合物和组合，以及使用所述化合物用于制造用于治疗和/或预防疾病的药物组合物，特别是作为单一剂或与其他活性成分结合使用的过度增殖障碍，如癌症疾病。
• Diazabicyclic central nervous system active agents
  申请人：——

  公开号：US20020019388A1

  公开（公告）日：2002-02-14

  Compounds of formula I 1 pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

  式I1的化合物，这些化合物的药物组合物，以及利用这些组合物来控制哺乳动物的突触传递。